Literature DB >> 32564944

Transthyretin amyloidosis: Testing strategies and model for center of excellence support.

Radislav Nakov1, Stayko Sarafov2, Mariana Gospodinova3, Andrey Kirov4, Teodora Chamova5, Tihomir Todorov6, Albena Todorova4, Ivailo Tournev7.   

Abstract

Appropriate testing strategies and strict model for Center Of Excellence (CoE) support are essential for the correct diagnosis, follow-up strategy and treatment plan for transthyretin (ATTR) amyloidosis. CoE is defined as a programme within a healthcare institution established to provide an exceptionally high concentration of expertise and related resources centred on a particular area of medicine, delivering associated care in a comprehensive, interdisciplinary fashion to afford the best patient outcome. Ideally, CoEs provide regular education and training for healthcare professionals and share knowledge and learning with other CoEs and specialists to ensure the highest standards of care. CoEs and testing strategies are of significant value to those with rare diseases and their families, as there is naturally low awareness among healthcare professionals, a phenomenon that potentially delays diagnosis and treatment. In this review, we focus on the importance of performing the most appropriate testing strategies for ATTR amyloidosis and establishing a CoE for this rare disease. We highlight our experience in establishing a CoE in Sofia, Bulgaria and define the fundamental steps needed to successfully launch a programme.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Centre of excellence; Rare disease; Testing strategies; Transthyretin amyloidosis

Mesh:

Substances:

Year:  2020        PMID: 32564944     DOI: 10.1016/j.cca.2020.06.029

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.

Authors:  Kathleen L Miller; Lewis J Fermaglich; Janet Maynard
Journal:  Orphanet J Rare Dis       Date:  2021-06-09       Impact factor: 4.123

Review 2.  Conceptualising centres of excellence: a scoping review of global evidence.

Authors:  Tsegahun Manyazewal; Yimtubezinash Woldeamanuel; Claire Oppenheim; Asrat Hailu; Mirutse Giday; Girmay Medhin; Anteneh Belete; Getnet Yimer; Asha Collins; Eyasu Makonnen; Abebaw Fekadu
Journal:  BMJ Open       Date:  2022-02-07       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.